Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.

Aging - 8 Nov 2021

Zhang Wenjing, Zhang Liwen, Jiang Hao, Li Yuting, Wang Suzhen, Wang Qinghua

Abstract excerpt

Recently several studies have demonstrated the implications of mutations in DNA damage response (DDR) pathways for immune checkpoint blockade (ICB) treatment. However, smaller sample sizes, lesser cancer types, and the lack of multivariate-adjusted analyses may produce unreliable results. From the Memorial Sloan-Kettering Cancer Center (MSKCC) cohort, we curated 1363 ICB-treated patients to evaluate the...

Topics

Join the communities discussing this publication.

Cohort Studies
DNA Damage
DNA Repair
Genetic Predisposition to Disease
Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 34747718
DOI: 10.18632/aging.203670
PMCID: PMC8610133

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.PMID 34747718Read ↗

Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor typesSemantic proximity Read ↗

DNA Damage Response Alterations and Immune Checkpoint Blockade Outcomes Across Multiple Cancers.Semantic proximity Read ↗

Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy.Semantic proximity Read ↗

A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancerSemantic proximity Read ↗

Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial CarcinomaSemantic proximity Read ↗

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.Semantic proximity Read ↗

DNA Repair and Signaling in Immune-Related Cancer TherapySemantic proximity Read ↗

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapySemantic proximity Read ↗

Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.Semantic proximity Read ↗

Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy.Semantic proximity Read ↗

Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a MatchmakerSemantic proximity Read ↗

Role of DNA repair defects in predicting immunotherapy responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.